Angion Provides Corporate Update and Reports First Quarter 2021 Financial Results
Retrieved on:
Monday, May 17, 2021
Angion is also currently evaluating ANG-3070, a tyrosine kinase receptor inhibitor for the treatment of fibrotic disease, in Phase 1.
Key Points:
- Angion is also currently evaluating ANG-3070, a tyrosine kinase receptor inhibitor for the treatment of fibrotic disease, in Phase 1.
- Additionally, Angion has preclinical programs for a rho kinase 2 (ROCK2) inhibitor and a CYP11B2 (aldosterone synthase) inhibitor.
- Such statements are subject to risks and uncertainties and actual results may differ materially from those expressed or implied by such forward-looking statements.
- Angion undertakes no obligation to update any forward-looking statement in this press release, except as required by law.\nThree Months Ended March 31,\n'